CTSO
Cytosorbents Crp
4.40$
+1.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 89.8% | 87.6% | 80.8% | 86.0% | 86.3% | 76.3% | 91.7% | 71.8% | 53.4% | 48.3% | 45.6% | 46.7% | |
| 42.6% | 47.2% | 54.1% | 71.9% | 68.3% | 44.7% | 79.4% | 58.2% | 35.0% | 26.5% | 6.9% | 14.1% | |
| 65.5% | 66.7% | 54.1% | 71.9% | 68.3% | 44.7% | 79.4% | 58.2% | 35.0% | 26.5% | 6.9% | 14.1% | |
| 9.7% | 5.8% | 14.8% | 9.2% | 12.0% | 16.3% | 5.7% | 5.1% | 9.0% | 11.4% | 15.5% | 17.1% | |
| 6.4% | 10.6% | 8.6% | 3.3% | 2.5% | 7.7% | 3.0% | 5.3% | 5.5% | 6.9% | 5.8% | 12.0% | |
| 2.9% | 5.0% | 5.9% | 5.8% | 9.7% | 10.9% | 2.4% | 20.7% | 17.0% | – | – | – | |
| 6.6% | 6.9% | 12.3% | 7.6% | 8.0% | 12.3% | 4.7% | – | – | – | – | 7.3% | |
| 6.6% | 6.9% | 12.3% | 7.6% | 8.0% | 12.3% | 4.7% | 5.3% | 6.9% | 7.3% | 7.9% | 7.3% | |
| 53.2% | 27.0% | 104.9% | 57.4% | 48.3% | 87.5% | 11.9% | 30.1% | 44.1% | 56.3% | 76.6% | 86.6% | |
| 53.2% | 27.0% | 62.8% | 32.6% | 20.0% | 36.3% | 11.3% | 15.3% | 15.4% | 27.3% | 20.7% | 22.0% | |
| 9.7% | 5.8% | 8.6% | 16.6% | 2.0% | 9.2% | 0.5% | 0.6% | 0.2% | 5.4% | 1.0% | 1.2% | |
| 8.2% | 6.1% | 13.7% | 5.2% | 6.0% | 7.4% | 2.7% | 3.1% | 2.6% | 7.1% | 7.1% | 6.5% | |
| 0.0% | 0.0% | 42.1% | 24.9% | 28.3% | 48.9% | – | – | 7.9% | 4.8% | 29.5% | 37.7% | |
| 46.8% | 73.0% | -4.9% | 42.6% | 51.7% | 12.5% | 88.1% | 69.9% | 55.9% | 43.7% | 23.4% | 13.4% | |
| -1,468.8% | -1,177.6% | -1,490.3% | -631.9% | -517.7% | -689.4% | -218.6% | -247.1% | -401.7% | -530.4% | -641.8% | -706.6% | |
| 169.8% | 221.1% | 262.4% | 114.6% | 93.8% | 117.8% | 43.2% | 48.4% | 3.4% | 4.2% | 5.7% | 7.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.